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Epithelial cell adhesion molecule (Ep-CAM; CD326) is used as a target by many immunotherapeutic approaches, but little data are
available about Ep-CAM expression in major human malignancies with respect to level, frequency, tumour stage, grade, histologic
tumour type and impact on survival. We analysed by immunohistochemical staining tissue microarrays with 4046 primary human
carcinoma samples from colon, stomach, prostate and lung cancers for both frequency and intensity of Ep-CAM expression under
highly standardised conditions. A total of 3360 samples were analysable. High-level Ep-CAM expression was observed in 97.7%
(n¼1186) of colon, 90.7% of gastric (n¼473), and 87.2% of prostate cancers (n¼414), and in 63.9% of lung cancers (n¼1287). No
detectable Ep-CAM staining was found with only 0.4% of colon, 2.5% of gastric, 1.9% of prostate cancers, and 13.5% of lung cancers.
The only significant correlation of Ep-CAM expression with tumour grading was observed in colon cancer where high-level Ep-CAM
expression on grade 3 tumours was down to 92.1% (Po0.0001). Adenosquamous and squamous carcinomas of the lung had a lower
percentage of high-level Ep-CAM expression compared to adenocarcinomas with 35.4 and 53.6%, respectively, and with 45.5 and
17.3% of tumours being Ep-CAM negative. With the exception of moderately differentiated colon carcinoma, where patients not
expressing Ep-CAM on their tumours showed an inferior survival (P¼0.0014), correlation of Ep-CAM expression with survival did
not reach statistical significance for any of the other cancer indications and subgroups. In conclusion, the data strongly support the
notion that Ep-CAM is a prime target for immunotherapies in major human malignancies. This is because the most common human
cancers show (i) a low frequency of Ep-CAM-negative tumours, (ii) a high frequency of Ep-CAM expression on cells of a given
tumour, and (iii) for most cancers, an insignificant influence of tumour staging, grading and histology on Ep-CAM expression.
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Epithelial cell adhesion molecule (Ep-CAM)is a type I transmem-
brane glycoprotein of Mr 40000Da, expressed in most normal
epithelial tissues on the basolateral surface. While no expression is
seen on squamous epithelia and hepatocytes, it is detected on
colon, gastric, prostatic and lung epithelium (Moldenhauer et al,
1987). Epithelial cell adhesion molecule is thought to function as a
homotypic intercellular adhesion molecule (Litvinov et al, 1994).
Its role in epithelial cell adhesion is dynamic and interconnected
with E-cadherin (Litvinov et al, 1997). By upregulation of Ep-CAM,
E-cadherin-mediated cell adhesion diminishes and the Ep-CAM
mediated adhesion becomes predominant. During organogenesis
in mice, Ep-CAM exhibits features of a morpho-regulatory
molecule, which, for instance, is involved in the development of
human pancreatic islets (Cirulli et al, 1998).
Epithelial cell adhesion molecule was discovered as one of the
first tumour-associated antigens by immunising mice with human
colon cancer cells followed by analysis of tumour-specific
monoclonal antibodies (Herlyn et al, 1979; Sears et al, 1982).
Epithelial cell adhesion molecule was then found to be expressed at
a high level and frequency not only on colon cancer tissues but on
most human adenocarcinomas (Went et al, 2004) as well as on
squamous cell carcinomas (Quak et al, 1990). In the case of breast
and ovarian cancers, Ep-CAM mRNA was found to be more than
100-fold overexpressed relative to normal epithelial tissues (Kim
et al, 2003; Osta et al, 2004).
Overexpression of Ep-CAM is linked to differentiation and cell
proliferation (Jordinson et al, 1999), although the molecular
mechanism is still poorly understood. In vitro, its overexpression
has been shown to be directly linked to stimulation of the cell cycle
and proliferation by upregulating c-myc and cyclin A/E (Munz
et al, 2004). In breast cancer cells, inhibition of Ep-CAM
expression by small inhibitory RNA diminishes cell proliferation,
migration and invasiveness of cells (Osta et al, 2004). Epithelial cell
adhesion molecule gene expression appears to be negatively
regulated by TNF-alpha through activation of NF-kappaB (Gires
et al, 2001). Upon cell cycle arrest by various chemotherapeutics,
Ep-CAM surface expression is enhanced (Flieger et al, 2001;
Thurmond et al, 2003). As Ep-CAM is involved in adhesion,
differentiation and cell proliferation, an influence of Ep-CAM
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sexpression on survival of cancer patients can be expected. In
breast and gall bladder cancer, patients with high Ep-CAM-
expressing primary tumours indeed showed a decreased survival
(Gastl et al, 2000; Spizzo et al, 2002; Spizzo et al, 2004; Varga et al,
2004). In clear cell renal cell carcinoma, Ep-CAM expression is
infrequent, but patients with Ep-CAM overexpressing tumours
show a trend to better survival (Kim et al, 2004; Seligson et al,
2004; Went et al, 2005). A similar correlation was reported for
gastric cancers (Songun et al, 2005). Very little information is
currently available with regard to the correlation of Ep-CAM
expression with survival and tumour staging for colon and lung
cancers, while more recent studies have explored larger sample
numbers of gastric (Songun et al, 2005) and prostate cancers
(Poczatek et al, 1999; Zellweger et al, 2005) for Ep-CAM
expression.
Due to its frequent and high-level expression, Ep-CAM
was selected as target antigen for a multitude of immunother-
apeutic approaches (Balzar et al, 1999). These include murine
and human monoclonal antibodies, antibody conjugates with
bacterial toxins and chemotherapeutics, and vaccines. Currently,
a number of Ep-CAM-specific immunotherapies are in phase I
and II clinical trials. These are anti-Ep-CAM antibodies ING-1
(de Bono et al, 2004), adecatumumab (Naundorf et al, 2002;
Prang et al, 2005), and edrecolomab (Himmler et al, 2003), as
well as an immunotoxin (Zimmermann et al, 1997; Di Paolo et al,
2003). It is therefore very important to understand which
human cancers are amenable to Ep-CAM-specific immunotherapy
based on Ep-CAM expression with respect to intensity, frequency
and disease stage. Likewise, it is interesting to investigate
a correlation of Ep-CAM expression with survival prognosis in
patients.
The aim of the present retrospective study was to investigate the
frequency and intensity of Ep-CAM expression in four major
human cancers by the use of tissue microarrays. This technology
allows for a simultaneous comparison of immunohistochemical
staining patterns and intensities across a large panel of tumour
samples. Variability due to fixation and staining procedures are
reduced to a minimum, while comparability is maximised.
Epithelial cell adhesion molecule expression results were corre-
lated for the first time with clinico-pathological parameters in
colon and lung cancers, while results from a large panel of gastric
and prostate cancer samples are being compared to published data.
Our results show that colon, gastric and prostate cancers as well as
adenocarcinoma of the lung are promising indications for
treatment with Ep-CAM-specific immunotherapies. Their frequen-
cies of high-level Ep-CAM expression 480% may even obviate the
need for prescreening of patients.
MATERIALS AND METHODS
Array composition
Primary tumours of colon, stomach, lung and prostate were
included in this study. Formalin-fixed and paraffin-embedded
tissue probes were retrieved from the archives of the Institute for
Pathology of the University Hospital Basel (Switzerland), the City
Hospital Triemli in Zu ¨rich (Switzerland) and the Departments of
Pathology of the University of Freiburg (Germany) and the Shiraz
University (Iran). Retrieval of tissue and clinical data was
performed according to the regulations of the local institutional
review board and data safety laws. The grade of the tumours was
obtained by a review of each case by a specialised pathologist. A
total of 1407 colon cancers (1261 adenocarcinomas NOS, five
medullary carcinomas, 119 mucinous carcinomas, five signet ring
carcinomas, four other types), 559 stomach, 1527 lung (367
adenocarcinomas (AC), 13 adenosquamous carcinomas, 82
bronchioloalveolar carcinomas, 258 large cell carcinomas, 63
neuroendocrine carcinomas, 744 squamous cell carcinomas
(SCC)) and 553 prostate carcinomas were then arrayed as
described before (Bubendorf et al, 2001). Briefly, tissue cylinders
with a diameter of 0.6mm were punched from representative
tumour areas of each donor tissue block and brought into a
recipient paraffin block. Multiple 4mm sections of the resulting
tissue microarray block were cut and mounted to an adhesive-
coated slide system.
Clinical data
All relevant patient data were anonymised. Sex, age and stage
according to the WHO/UICC 1997 were recorded in subsets of
gastric, colon, lung and prostate cancers. In prostate cancers, the
Gleason score was available. Grade was also known in colon and
lung cancers. Additionally, the survival time was recorded in
tumours from the colon, lung and prostate, but not stomach.
Overall survival (OS) was calculated from the date of diagnosis
until death from any cause or date of last contact for living
patients. The cause of death was recorded in a subset of patients to
calculate the tumour-specific survival.
Immunohistochemistry
Standard indirect staining procedures were used for immunohis-
tochemistry (ABC-Elite-Kit, Vector Laboratories, Burlingame, CA,
USA). After heat-induced pretreatment (water bath, 30min, 991C
in target retrieval solution buffer (DAKO code S1699, DAKO,
Glostrup, Denmark)) for antigen retrieval, a mouse monoclonal
anti-Ep-CAM-antibody (ESA, clone VU-1D9, Novocastra, New-
castle upon Tyne, UK) was applied for 2h at a dilution of 1:50 at
371C. The slides were then incubated with the secondary,
biotinylated antibody. Osmium-enhanced diaminobenzidine was
used as the chromogen. Counterstaining was carried out with
Harris’ haematoxylin. Only fresh cut slides were stained simulta-
neously to minimise the influence of slide ageing and maximise
repeatability and reproducibility of the experiment. For negative
controls, the primary antibody was omitted, as positive controls
the internal normal tissues with known EpCam positivity were
used. For each sample, staining intensity (0, faint to moderate,
intense) and percentage of positive tumour cells was estimated. A
case was considered strongly positive if the antibody detected
470% positive cells, otherwise weakly positive, or negative if no
cells were stained. Staining intensity was recorded, but not used for
correlation with clinical findings, as it can vary depending on the
manner of tissue fixation. Cytoplasmic staining alone was
considered as nonspecific as Ep-CAM is localised on the cell
membrane. These cases were excluded from analysis. The slides
were all evaluated in one day by one experienced pathologist (GS)
to minimise inter- and intraobserver variability of the results.
Statistics
The software used for statistical analysis was statview 5.0 (SAS
Institute Inc., NC, USA) The Fisher’s exact test and the w
2 test were
used to compare Ep-CAM expression and clinical and morpholo-
gical tumour characteristics. For survival analysis, patients with
Ep-CAM weakly to moderately positive and negative tumours were
grouped together to emphasise on Ep-CAM overexpressing
tumours. Survival curves were plotted according to Kaplan–
Meier. The univariate association between individual clinical
features and overall survival (OS) was determined with the log-
rank test. Factors independently associated with OS were identified
in a multivariate analysis by the Cox proportional hazards
regression model. The limit of significance for all analyses was
defined as a P-value o0.05; two-sided tests were used in all
calculations.
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Clinical information was available for 3746 tumours (Table 1),
whereas Ep-CAM staining results from tissue microarrays were
obtained for 3360 tumour samples. A total of 686 tumour samples
(17%) on microarrays could not be analysed due to issues of
sample quality. Figure 1 shows examples for different intensities of
Ep-CAM-specific immunohistochemical staining of tissue micro-
array samples from four colon cancer patients.
In all four tumour entities, staining was predominantly
membranous but cytoplasmic staining could also be seen in cases
with an intense staining. In total, 74.1% of the 3360 tumours
showed a high-level Ep-CAM staining. In total, 85.1% of samples
showed a staining in 470% of tumour cells. Of note, 92.2% (2118
of 2297 cases) of tumours with an Ep-CAM-positive cell fraction
470% had at the same time the highest staining intensity score,
indicating a marked coincidence of high-level staining intensity
with a high fraction of positive tumour cells. As intensity is
typically subdued to variations following tissue fixation and most
notably staining procedures, the equal high staining intensity in
the majority of cases well reflects the highly optimised staining
procedure, whereas the high percentage of positive cases indicates
an excellent preservation of the investigated antigen in the samples
selected for construction of microarrays. This obviously led to an
almost binary data set in which only 11.6% of the 3360 tumour
samples showed a positive tumour cell fraction of less than 70%,
and on average 19.6% a weak to moderate staining intensity. The
observed ‘black or white’ pattern was further emphasised by the
scoring system, correlating only strongly positive tumours with
survival data. On average, Ep-CAM expression was completely
absent from only 5.9% of tumours (198 cases) based on
immunohistochemical analysis. An overview of staining results
across all tumour samples is shown in Table 2.
Table 1 Clinical characteristics of analysed patients and tumors
Carcinoma
Lung Colon Stomach Prostate All
Number 1534 1186 473 553 3746
Sex
Female 201 735 117 0 1053
Male 826 670 311 553 2360
Median age
(years, range)
61.9
(29–87)
69.7
(36–96)
59
(27–92)
64.7
(45–92)
Survival
(months, range)
36.4
(0–200)
50.5
(0–152)
82.5
(0–345)
Stage
pT1 276 62 3 36 377
pT2 864 202 39 401 1506
pT3 250 892 362 88 1592
pT4 104 222 10 22 358
Nodal stage
pN0 776 703 153 509 2141
pN1 335 355 245 14 949
pN2 338 292 64 1 695
pN3 39 0 7 0 46
Metastases
pM0 1394 NA 445 542 2381
pM1 94 NA 25 0 119
Grade (Gleason score in prostate carcinoma)
1 140 31 NA
2 362 1176 NA
3 0 177 NA 3
41 7
5 134
6 169
7 191
81 7
91 9
10 2
Stage, nodal stage and metastases according to the WHO/UICC (1997). NA: Not
available.
Figure 1 Examples of Ep-CAM staining of four human colon carcinoma
samples from a tissue microarray. (A) Sample with no Ep-CAM staining.
Samples with weak (B), moderate (C) or intense (D) Ep-CAM staining.
Note that in (B) and (C) the staining intensity and quantity of positive
tumour cells are different. Inlets showing detailed view of the membrane
localised staining product.
Table 2 Frequency of Ep-CAM overexpression in major human cancers
Ep-CAM expression
Tumour entity n
Negative
(%)
Weak/
moderate (%)
Strong
(%)
All 3360 5.9 11.6 82.5
Colon
Adenocarcinoma NOS 1086 0.3 1.7 98.0
Medullary carcinoma 5 20.0 0 80.0
Mucinous carcinoma 88 0 4.5 95.5
Signet ring cell carcinoma 4 0 0 100.0
Other types 3 0 0 100.0
Stomach
Stomach carcinoma 473 2.5 6.8 90.7
Lung
Adenocarcinoma NOS 317 5.3 13.9 80.8
Adenosquamous carcinoma 11 45.4 18.2 36.4
Bronchioloalveolar carcinoma 60 3.3 21.7 75.0
Large cell carcinoma 224 15.1 17.9 67.0
Neuroendocrine carcinoma 56 16.1 19.6 64.3
Squamous cell carcinoma 619 17.3 29.1 53.6
Prostate
Prostate carcinoma 414 1.9 10.9 87.2
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cancer
In the colon cancer microarray (Table 3), samples from 1186
patients were analysable. Most of the cases showed an intense
staining signal in the vast majority of tumour cells. Only seven
tumours (0.6%) showed a faint staining intensity, whereas 1152
tumours (97.1%) showed a strong staining intensity. In total,
97.7% of cases (n¼1159) showed Ep-CAM expression in more
than 70% of tumour cells.
Highly differentiated colon cancers expressed Ep-CAM signifi-
cantly more frequently and strongly than the other colon cancers
(Po0.0001). However, the low differentiated colon cancers of
grade 3 were still strongly positive for Ep-CAM in 92.1% of cases.
In an univariate survival analysis, the lymph node status (pN0 vs
pNþ, Po0.0001), vascular invasion (Po0.0001) and postopera-
tive chemotherapy (Po0.0001) were significant regarding tumour-
specific survival. Because Ep-CAM expression and tumour grade
showed a significant association, the different grades were
analysed separately. Patients with Ep-CAM negative, moderately
differentiated colon cancers (Grade 2) showed a significantly
inferior tumour-specific survival (OR 5.421, 95% CI 1.685–17.442,
P¼0.0014, n¼284), whereas in the other subgroups patients with
strongly Ep-CAM expressing tumours showed no such trend
towards a better survival. This association in the G2 colon
carcinomas remained significant in a multivariate analysis
including Ep-CAM expression (OR 11.175, 95% CI 3.327–37.534,
Po0.0001), the lymph node status (OR 3.169, 95% CI 1.768–5.680,
P¼0.0001), vascular invasion (OR 2.408, 95% CI 1.345–4.309,
P¼0.0031), whereas postoperative chemotherapy (OR 0.772, 95%
CI 0.421–1.413, P¼0.4006) showed no statistical significance.
Epithelial cell adhesion molecule expression in stomach
cancer
On the stomach cancer microarray (Table 4), 473 cases were
analyzable. In total, 90.7% of the tumours (n¼429) expressed
Ep-CAM on 470% of cells and 85.8% of the cases (n¼406)
showed the highest level of staining intensity. Epithelial cell
adhesion molecule frequency was lowest in pT4 tumours (77.8%),
while all other subgroups showed Ep-CAM expression in more
than 80% of tumours. No significant correlation of Ep-CAM
expression between primary tumour, nodal or metastasised stage
was found. In this group of patients, no data on patient survival
were available for correlation with Ep-CAM expression.
Epithelial cell adhesion molecule expression in prostate
cancer
In the prostate cancer microarray, 414 cases were analyzable
(Table 5). Of these, 361 cases (87.2%) showed a strong Ep-CAM
Table 3 Expression of Ep-CAM in colon carcinoma
Ep-CAM expression
n
Negative
(%)
Weak/
moderate (%)
Strong
(%) P-value
a
All 1186 0.4 1.9 97.7
Histology
Adenocarcinoma NOS 1086 0.3 1.7 98.0
g
Medullary carcinoma 5 20.0 0.0 80.0
Mucinous carcinoma 88 0 4.5 95.5 o0.0001
Signet ring cell carcinoma 4 0 0 100
Other types 3 0 0 100
Stage
pT1 47 0 0 100.0 g
pT2 171 0.6 1.2 98.2 NS
pT3 766 0.2 2.0 97.8
pT4 187 0.5 2.7 96.8
Grade
1 23 0 0 100 g 2 1001 0.1 1.3 98.6 o0.0001
3 153 2.0 5.9 92.1
Nodal stage
N0 603 0 1.8 98.2 g N1 309 0.7 1.9 97.4 NS
N2 241 0.4 2.5 97.1
aAccording to w
2.N S¼Not significant.
Table 4 Expression of Ep-CAM in gastric carcinoma
Ep-CAM expression
n
Negative
(%)
Weak/
moderate (%)
Strong
(%) P-value
a
All 473 2.5 6.8 90.7
Stage
pT1 1 0 0 100.0 g NS pT2 27 0 18.5 81.5
pT3 305 3.6 6.2 90.2
pT4 9 0.0 22.2 77.8
Nodal stage
N0 130 4.6 6.2 89.2 g NS
N1 209 1.9 8.1 90.0
N2 52 3.8 3.9 92.3
N3 6 0 16.7 83.3
Distant metastases
M0 379 2.9 7.1 90.0 g NS
M1 18 5.5 0 94.5
aAccording to w
2.N S¼Not significant.
Table 5 Expression of Ep-CAM in prostate carcinoma
Ep-CAM expression
n
Negative
(%)
Weak/
moderate (%)
Strong
(%) P-value
a
All 414 1.9 10.9 87.2
Stage
pT1/2 321 2.2 11.8 86.0 g pT3 70 1.4 8.6 90.0 NS
pT4 19 0 0 100.0
Gleason score
3 2 0 0 100.0
g
4 11 0 0 100.0
5 106 1.8 5.7 92.5
6 127 1.6 10.2 88.2 NS
7 139 2.1 13.0 84.9
8 11 9.1 27.3 63.6
9 16 0 31.2 68.8
10 2 0 0 100.0
Nodal stage
N0 378 2.1 10.9 87.0 g N1 9 0 22.2 77.8 NS
N2 1 0 0 100.0
aAccording to w
2.N S¼Not significant.
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sexpression. Epithelial cell adhesion molecule expression and stage
or grade according to Gleason did not correlate. In univariate
survival analysis, there was the expected significant correlation
between Gleason score and survival in (Po0.0001). However, there
was no correlation of Gleason score or survival with Ep-CAM
expression.
Epithelial cell adhesion molecule expression in lung
cancers
In the lung cancer array, 1287 cases were analyzable (Table 6). On
average, 64% of cases (n¼823) showed a high Ep-CAM expression
score. An intense staining signal was detected in 51% of cases
(n¼660). Squamous cell (53.6%, n¼332), neuroendocrine (64.3%,
n¼36) and large cell carcinomas (67%, n¼150) were expressing
Ep-CAM less frequently at a high level than adenocarcinomas
(80.8%, n¼256) (Po0.0001). There was no association of stage or
grade and Ep-CAM expression in any of the histological
subgroups.
In univariate survival analysis, the expected significant correla-
tion between tumour stage and survival was observed (Po0.0001).
Because the different histological subgroups showed varying Ep-
CAM expression, they were analysed separately. No definite
correlations were found regarding Ep-CAM expression, grade
and survival in any of the histological entities, although sample
bias cannot be completely excluded as our tumour collective did
not contain poorly differentiated tumours. There was a trend
toward a longer survival in patients with adenocarcinomas, large
cell and bronchioloalveolar carcinomas and strong Ep-CAM
expression. This trend was inversed in SCC.
DISCUSSION
This is the largest analysis of Ep-CAM expression in major human
malignancies performed to date. It employed a highly reproducible
and standardised high-throughput array technology, which allows
comparison of staining intensity and frequency for a large set of
tissue samples. Comparability of IHC data within and across
studies is frequently hampered by the use of distinct fixation,
staining and antibody detection protocols. In addition, different
antibodies are used in the literature to stain a particular target
antigen. In the present analysis, all these parameters were kept
constant. The use of high sample numbers, one of the main
advantages of array technology, resulted in reaching statistically
meaningful conclusions. With lung, colon, prostate and gastric
cancers, we have selected four of the most frequent cancers in the
industrialised world. Epithelial cell adhesion molecule expression
in breast cancer has been previously published for more than 1700
patient samples (Gastl et al, 2000; Spizzo et al, 2002; Spizzo et al,
2004).
In primary tumours of colon, lung, prostate and stomach, Ep-
CAM was on average significantly expressed in 94.1% of 3360
cases. In our analysis, Ep-CAM expression showed a tendency to
be binary with the larger group consisting of tumours with high
staining intensity on a major fraction of tumour cells, and a much
smaller group expressing Ep-CAM only at weak or moderate levels,
or not all. In well and poorly differentiated colon cancers, and lung
and prostate cancer, no obvious correlation of Ep-CAM expression
with survival, tumour stage or grade was observed. Gastric cancer
could not be analysed for a correlation of Ep-CAM expression with
survival because no patient survival data were available for this
indication. Previous studies investigated the influence of Ep-CAM
expression on survival in a number of other carcinoma. Epithelial
cell adhesion molecule upregulation was an independent marker
for poor survival in lymph node positive breast cancers (Spizzo
et al, 2004), and gall bladder cancers (Varga et al, 2004). In
contrast, improved survival was found associated with Ep-CAM
upregulation in clear cell renal cell carcinoma (Kim et al, 2004;
Seligson et al, 2004; Went et al, 2005), and gastric cancers (Songun
et al, 2005). Here, we observed that survival of patients in the
subgroup of moderately differentiated colon cancers also showed a
significant positive correlation with Ep-CAM expression. Consis-
tent with previous reports, we could not find an influence of
Ep-CAM expression on patients’ survival outcome in lung and
prostate cancers (Poczatek et al, 1999; Piyathilake et al, 2000).
How can the effect of Ep-CAM overexpression on survival be so
different depending on cancer indication, and for subgroups
within a given indication? The emerging functional importance of
Ep-CAM for tumour cells would be more consistent with the
phenotype of breast and gall bladder cancers, where Ep-CAM
overexpression is an independent predictor of poor survival
(Spizzo et al, 2004; Varga et al, 2004). Overexpressed Ep-CAM was
shown to provide a potent growth stimulus to tumour cells
enabling proliferation (Munz et al, 2004), and led to an increased
invasiveness and migration of tumour cells presumably due to E-
cadherin antagonism (Litvinov et al, 1997; Osta et al, 2004). It is
likely that Ep-CAM exerts the same functions in cells of primary
tumours and metastases, which would well explain why Ep-CAM
shows high-level and largely uniform expression on tumour cells
of most patients with adenocarcinoma of lung, prostate, breast,
colon, and gastric cancer. In many of these cancers, the fraction of
Ep-CAM-negative tumours is very small. For instance, in the
present study, only four out of 1186 colon cancer samples were Ep-
CAM-negative. In breast cancer, the analytical situation was better
because approximately 10% of tumours are Ep-CAM negative
(Spizzo et al, 2004). Hence, despite very large sample numbers, it
may be still difficult to accrue large enough sample populations for
statistical comparison of Ep-CAM-negative with positive tumours.
As a consequence, studies have to rely on comparing different
Table 6 Expression of Ep-CAM in lung carcinoma
Ep-CAM expression
n
Negative
(%)
Weak/
moderate (%)
Strong
(%) P-value
a
All 1287 13.5 22.5 63.9
Histology
AdenoCa
b NOS 317 5.4 13.9 80.8
g
o0.0001
Adenosquamous Ca
b 11 45.5 18.2 36.4
Bronchioloalveolar Ca
b 60 3.3 21.7 75.0
Large cell Ca
b 224 15.2 17.9 67.0
Neuroendocrine Ca
b 56 16.1 19.6 64.3
Squamous cell Ca
b 619 17.3 29.1 53.6
Stage
pT1 224 8.5 22.3 69.2 g
0.0517 pT2 738 13.6 22.0 64.5
pT3 217 17.1 26.3 56.7
pT4 85 18.8 20.0 61.2
Grade
1 100 4.0 19.0 77.0 g NS 2 295 8.5 16.6 74.9
Nodal stage
N0 639 13.6 23.2 63.2
g NS
N1 293 13.3 19.1 67.6
N2 292 13.7 24.3 62.0
N3 34 17.7 26.5 55.9
Distant metastases
M0 1183 13.6 22.7 63.7 g NS M1 82 13.4 20.7 65.9
aAccording to w
2.
bCa, Carcinoma. NS¼Not significant.
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sexpression levels of Ep-CAM, the accuracy of which is limited by
the semiquantitative nature of immunohistochemical staining
procedures.
A hallmark of tumour cells is de-differentiation, which typically
goes along with the loss of expression of differentiation markers
(Kiemer et al, 2001; Peinado et al, 2004). Epithelial cell adhesion
molecule is an epithelial differentiation marker, which is
frequently expressed on normal epithelial cells (Winter et al,
2003). Loss of Ep-CAM expression is therefore a likely conse-
quence of tumour cell de-differentiation, as for instance is seen for
the epithelial differentiation antigen E-cadherin (Sulzer et al,
1998). On the other hand, overexpression or maintenance of Ep-
CAM expression on tumour cells relative to normal epithelia may
then be an indication that its presence confers a benefit to tumour
cells. The level of Ep-CAM expression on tumour cells will then
reflect a balance of reduced expression due to de-differentiation
and over- or maintained expression as a consequence of positive
selection of a certain growth phenotype. The survival difference
between patient populations with high and low Ep-CAM-expres-
sing tumours should therefore be seen in light of an antagonism
between de-differentiation and positive selection.
While both high and low Ep-CAM-expressing tumours may still
benefit from growth-stimulatory and metastatic properties of Ep-
CAM, the population of low and no Ep-CAM expressors may have
undergone further de-differentiation events to a level were reduced
expression or loss of Ep-CAM has been compensated for by
overexpression of other growth-promoting proteins. Examples are
growth factor receptors like HER-2 and EGFR, which in contrast to
Ep-CAM, are upregulated as a consequence of gene amplification
events (Simon et al, 2003; Al-Kuraya et al, 2004). Future studies are
needed to explore whether reduced Ep-CAM expression or its loss
is linked to a concomitant overexpression of other proteins with
oncogenic potential. If this functional compensation is specific for
tumour type, it could explain why Ep-CAM expression has such
distinct effects on survival prognosis over different indications.
Its high-level, frequent and homogenous expression on human
adenocarcinoma make Ep-CAM an ideal target for antibody-based
immunotherapeutic approaches. Epithelial cell adhesion molecule
is currently targeted by two principally different approaches in
cancer therapy: passive and active immunotherapy. The first
antibody used in passive immunotherapy was edrecolomab, a
murine IgG2a antibody targeting Ep-CAM (Sears et al, 1984;
Riethmuller et al, 1994). The therapeutic effect of this antibody
administered alone or in combination with chemotherapy or GM-
CSF (Mellstedt et al, 2000) was not conclusive, but it showed a very
benign safety profile (Fields et al, 2002; Punt et al, 2002; Hartung
et al, 2005). To reduce immunogenicity and enhance antibody-
dependant cytotoxicity, complement dependant cytotoxicity and
serum half-life, humanised antibodies ING-1 (de Bono et al, 2004),
3622W94 (Abdullah et al, 1999; Martin et al, 1999) and fully
human IgG1 antibody MT201 (adecatumumab) (Naundorf et al,
2002; Brischwein et al, 2005) were developed. All showed much
higher in vitro cytotoxic activity than edrecolomab, but the two
high-affinity antibodies ING-1 and 3622W94 turned out to be
much less tolerable than edrecolomab due to induction of acute
pancreatitis. Conjugation of the Ep-CAM-specific murine mono-
clonal antibody 323/A3 human with beta-glucuronidase is a
prodrug approach designed to locally augment the anti-tumour
effect of doxorubicin (Houba et al, 2001). A fusion protein between
a single-chain antibody and a bacterial toxin is currently being
tested for local treatment of head and neck tumours in a phase I
trial (Quenneville et al, 2005), and has shown extraordinary
antitumour activity and potency in a xenograft model (Di Paolo
et al, 2003). Epithelial cell adhesion molecule was also selected as
target for bi- and trispecific antibody therapies. Three T-cell
activating, single-chain bispecific antibodies were shown to
potently eradicate established and disseminated tumours in
immunodeficient and -competent mouse models (Peters et al,
2004; Brischwein et al, 2005; Schlereth et al, 2005a,b), and a related
bispecific antibody called E3Bi demonstrated high in-vitro
cytotoxicity (Ren-Heidenreich et al, 2004). The trifunctional
antibody catumaxomab (anti-Ep-CAM anti-CD3) has been safely
administered in a phase I/II study to patients suffering from
malignant ascites (Stroehlein et al, 2005). Bispecific antibodies that
link adenovirus to Ep-CAM are experimentally used in combina-
tion with recombinant adenoviral vectors for cancer gene therapy
(Haisma et al, 1999), and adenoviral vectors expressing virus with
an anti-Ep-CAM surface protein were also constructed (Oosterhoff
et al, 2005).
One active immunotherapy approach is using IGN101 (for-
mulated edrecolomab) for induction of anti-Ep-CAM anti-
idiotypic antibodies (Zaloudik et al, 2002). This vaccination was
shown to be safe, reduce Ep-CAM positive tumour cells in
circulation and prolong survival of patients with metastatic rectal
cancer (Himmler et al, 2005). Current experimental approaches are
using the Ep-CAM promoter to control the expression of
therapeutic genes (Gires et al, 2004), and short interfering RNA
for the silencing of Ep-CAM expression, which resulted in a 35–
80% decrease in proliferation of breast cancer cell lines (Osta et al,
2004). Lastly, the Ep-CAM protein is being used as a vaccine to
elicit by various approaches the induction of specific T and B cell
responses (Mosolits et al, 2004, 2005; Neidhart et al, 2004).
The emerging results from Ep-CAM-targeting immunotherapies
show a wide utility of the target antigen. Although Ep-CAM is
also expressed on normal epithelia, a lower expression there
compared to tumour cells (Kim et al, 2004; Osta et al, 2004) and a
possible sequestration of Ep-CAM between epithelial cells
(McLaughlin et al, 2001) appears to open a therapeutic window.
This is supported by the benign safety profile of certain Ep-CAM
targeted therapies such as edrecolomab, adecatumumab and
vaccination approaches with the autoantigen. In indications
showing a strong correlation between Ep-CAM overexpression
and poor survival prognosis, selective ablation of Ep-CAM positive
cells by the above therapeutic approaches may translate into a
survival benefit. In indications with a neutral or positive effect of
Ep-CAM overexpression on survival, the high proportion of Ep-
CAM positive cells in tumours may still be efficacious in particular
if the targeted immunotherapy is combined with chemotherapeu-
tics, and if used in adjuvant settings as are characterised by low
tumour load.
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